2025.06.15 Boston · USA



2025.06.15 Boston · USA

Others

ASEAN

EUROPE

JAPNA

KOREA

AUSTRALIA

45% China US

MENA

The proportion of Attendees

INDIA

CGT **Others** 24% Chemicals Synthetic Biology Antibody Drugs ADC-

Nuclesic Acid Drugs

Profile

About BIOCHINA Global Forum

The BIOCHINA Global Forum, an international brand launched by BIOCHINA, embraces the theme "Together for Innovation" to enhance global engagement. This past June, the Forum gathered 200 international attendees and exhibitors from numerous countries at its event in San Diego.

With events now held in key locations such as Boston, San Diego, and Seoul, the BIOCHINA Global Forum fosters local technology and industry exchanges through forums and networking opportunities. The Forum also provides global partners with valuable insights into the growth trends of China's biopharmaceutical industry, sharing expertise and promoting collaboration across the global bio-industry.

200 participants

Date June

Attendees


C-levels from Chinese Biotech companies and CXOs C-levels from upstream service providers C-levels from international Biotech companies and **MNCS**

The BIOCHINA Global Forum provides a platform for connecting the entire industry chain of Chines biopharmaceutical companies with global partners from the US, Europe, Korea, UAE and beyond.

Previous - BIOCHINA Global Forum @ San Diego



2025.06.15 Boston · USA



• Conference Agenda •

12:00-13:00 Check-in

13:00-13:10 Welcome Speech

13:10-15:50 Summit Sessions

15:50-16:10 Tea Break

16:10-18:00 Roundtables on Investment, Licensing and Strategic Collaboration

18:00-20:00

Reception



Register now

For inquiries:

biochina@enmore.com













Organizer: SENMORE BIO Co-Organizer: BCIC Strategy Partner: Henlius WOLD Booth Sponsor: WY ProBio Branding Sponsor: Boker Jewickenzie AT ON

BIO CHINA Global Forum

2025.06.15 Boston · USA

Conference Agenda

12:00-13:00

Registration

13:00-13:10

Welcome Speech



Vera Deng, Founder&CEO, Enmore BIO



Min Yi, President, BCIC



Yongping Cao, Representative, CCPIT USA Representative Office



Weiming Jiang, Director of Suzhou Industrial Park Investment **Promotion Commission**

Summit Sessions

13:10-13:30

Keynote Speech: Innovationand BD trends from Chinese biotechs



Speaker: Helen Chen, Greater China Managing Partner, L.E.K. Consulting;

13:30-14:10

Panel Discussion: Exploration of Newco Deal Models



Moderator: Han Zhang, Director, BCIC



Panelist: Mingjiu Chen, Founder, President & CEO, Biosion Inc.,



Stephan Lensky, CBO&COO, EpimAb Biotherapeutics Inc.



Su Zhang, Managing Director, CoDevCo LLC



Xin Tao, Partner, Baker & McKenzie LLP

14:10-14:50

Panel Discussion: Co-building Innovative Industry Ecosystems with Biotech, Big Pharma, MNCs, and Investors



Moderator: Charles Lin, Licensing BD, WuXi Biologics



Panelist: Qiusong Tang, Head of Roche Accelerator



Max Hunt, Partner (Value, Access & Pricing) of Trinity Life Sciences



Jiamin Zhuo, Global Strategy Insight Director, EMD Serono(Merck KGaA)



Tatiana Yglesias, Executive Director, Portal Innovations Boston

14:50-15:50

Panel Discussion: Why choose to cooperate with Chinese biopharmaceutical companies: Trust & Quality



Moderator: Ping Cao, SVP & CBO, Henlius



Panelist: Jim Broderick, CEO & Founder, Palleon Pharmaceuticals, Inc.



Satbir Kaur, Head of Alliance Management and Integration, Organon



Suresh Keshwani. Associate Vice President-Global Business



David J Portman, CEO, Sermonix Pharmaceuticals

Development, Specialty brands, Accord Healthcare



Shwetanuj Saha, Vice President – Global Head of Strategy, Portfolio and Business Development - Biologics, Dr. Reddy's Laboratories Ltd.

15:50-16:10

Tea Break











2025.06.15 Boston · USA

Roundtables on Investment, Licensing and Strategic Collaboration

16:10-17:00

Section1



Topic 1: Beyond PD-(L)1/VEGF **Bispecifics: Innovating Towards Definitive OS Benefits**



Speaker: Jason Yang, CEO & President of R&D, Executive Director of the Board, CStone Pharmaceuticals



Topic 2: Navigating Legal and Regulatory Risks in SinoU.S. **Cross Border Transaction**



Speaker: Mai Zymaris, Partner, Ice Miller: TaeSoo Sean Kim, Partner, Ice



Topic 3: Navigating U.S. M&A Strategies for Chinese Biotech Firms: Compliance, Valuation & **Deal Structuring**



Speaker: Marc Spencer Appel, CEO, Pacific Bridge NY



Topic 4:Beyond the Price Tag: How Innovative Regulatory and Mar ket Access Strategies Expedite Approval and Sha pe Oncology Commercialization in the US and EU





Speaker: **Hui Huang**, Founder & CEO of CSD-PARTNERS; Fommer Vice President, Head of Global Value & Access Oncoloay of Takeda Guilin Huang Former SVP, Head of Development, AnHeart



Topic 5: Pfizer Discovery Network: Harnessing External Innovation to Deliver Breakthroughs



Speaker: Marija Tadin-Strapps, Head of Discovery Network. Pfizer



Topic 6: Al accelerated drug discovery



Speaker: Li Xing, Founder/CEO, LexBio Therapeutics



Topic 7: EnCureGen Pharma: a cuttingedge mRNA platform-based biotech



Speaker: Aimin Hui, Founder, Chair & CEO. EnCureGen Pharma



Topic 8 : Pathway to Global Market: Quality-driven CMC Strategies for Biologics



Speaker: Wei Huang, President, Henlius; Heidi Gong, CMC Operation GM. Henlius











2025.06.15 Boston · USA

Roundtables on Investment, Licensing and Strategic Collaboration

17:10-18:00

Section2



Topic 1 : AstraZeneca's Global Collaboration Strategy



Speaker: Nikhil Mutyal, Head of Search and Evaluation - Respiratory & Immunology, AstraZeneca; Nathan Styles, Head of Search and Evaluation, CVRM, Astrazeneca



Topic 2 : Qilu Pharmaceutical: Innovation in China for Global Collaboration



Speaker: Xiangbin XU, VP of BD&L, Head of Boston Innovation Center, Qilu Pharmaceuticals:

Michael Conti, Associate Director, Business Development, Oilu Pharmaceuticals



Topic 3: Huadong Medicine - Innovative ADC Oncology and GLP-1/GIP Therapeutics **Development**



Speaker: Liu Dongzhou Jeffrey, CSO, Huadong Medicine



Topic 4: HTD1801: A late-stage first-in-class dual mechanism of AMPK activation and NLRP3 inhibition for Cardiovascular-Kidney-Metabolic diseases



Speaker: Liping Liu, CEO, HighTide





Topic 5: Bio-Thera Solutions Innovative and Biosimilar Partnering Strategies

Speaker: Bert Thomas, Senior Vice President, Business Development, Bio-Thera Solutions



Topic 6



Speaker: Sam Waksal, CEO, Graviton Bioscience: Rui Wu, SVP, Head of Research & Preclinical and Chief CMC Officer ,Graviton Bioscience



Topic 7: Indias thrust on Biotechnology. Vision 2047



Speaker: Murali Panchapagesa Muthuswamy, Hon.President - ABLE -Association of Bitoechnology Led Enterprises:

Mr. G. S. Krishnan, Stakeholder Advisor, Novonosesis



Topic 8: Biopharmaceuticals and Biosimilars. Perspective from a Company Based in LatAm and Spain



Speaker: Mauricio Seigelchifer, Cofounder and Innovation Director of Mabxience

2025.06 Boston · USA





